FLT3 and acute myeloid leukemia: An FLT3 inhibitor treatment study demonstrated that FLT3 (26%), epigenetic modifiers (16%), RAS/MAPK pathway genes (13%), WT1 (7%) and TP53 (7%) are emerging mutations identified in relapsed AML patients [8].